Protease assay for therapeutic drug monitoring

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S024000, C435S007720

Reexamination Certificate

active

10494903

ABSTRACT:
The present invention concerns a further development and use of biological assays to determine the amount or concentration of an active ingredient present in a sample. The enzyme assay of the present invention determines the amount or concentration of protease inhibitors, including retroviral protease inhibitors such as HIV inhibitors.

REFERENCES:
patent: 4546076 (1985-10-01), Degelaen et al.
patent: 4918001 (1990-04-01), Kolde
patent: 5576177 (1996-11-01), Fridland et al.
patent: 5843946 (1998-12-01), Vazquez et al.
patent: 6017723 (2000-01-01), Rao et al.
patent: 6243980 (2001-06-01), Bronstein et al.
patent: 0 428 000 (1991-05-01), None
patent: 0 518 557 (1992-12-01), None
patent: WO 97/27319 (1997-07-01), None
patent: WO 97/27480 (1997-07-01), None
patent: WO 99/50579 (1999-10-01), None
patent: WO 99/54734 (1999-10-01), None
patent: WO 99/67417 (1999-12-01), None
patent: WO 01/57245 (2001-08-01), None
patent: WO 02/23186 (2001-09-01), None
patent: WO 01/79540 (2001-10-01), None
patent: WO 02/23186 (2002-03-01), None
patent: WO 02/38792 (2002-05-01), None
Guidance for Industry; U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Nov. 1999.□□Http://www.fda.gov/cder/guidance/2635fnl.pdf.
Zhang et al. Drur Resistance During Indinavir Therapy is Caused by Mutations in the Protease Gene and in its Gag Substrate Cleavage Sites: Journal of Virology, vol. 71, No. 9 (1997) pp. 6662-6670.
Vance et al. Conformational Selectivity of HIV-1 Protease Cleavage of X-Pro Peptide Bonds and its Implications; The Journal of Biological Chemistry, vol. 272, No. 25 (1997) pp. 15603-15606.
Aarnoutse, Re, et al., “High-Performance Liquid Chromatography of HIV-Protease Inhibitors in Human Biological Matrices”Journal of Chromatography, 2001, 764, 363-384.
Dailly, E. et al., “High-Performance Liquid Chromatographic Assay to Determine the Plasma Levels of HIV-Protease Inhibitors (Amprenavir, Indinavir, Nelfinavir, Ritonavir and Saquinavir) and the Non-Nucleoside Reverse Transcriptase Inhibitor (Nevirapine) after Liquid-Liquid Extraction”,Journal of Chromatography B2001, 758(2), 129-135.
Gulnik, S. et al., “Enzymatic Bioassay for Therapeutic Drug Monitoring of HIV Protease Inhibitors”,Antiviral Therapy, 2002, 7, S78.
Kakiuchi, N., et al. “A High Throughput Assay of the Hepatitis C Virus Nonstructural Protein 3 Serine Proteinase”,Journal of Virological Methods, 1999, 80, 77-84.
Leela, John et al., “Role of Therapeutic Drug Monitoring for Protease Inhibitors”,The Annals of Pharmacotherapy, 2001, 35(6), 745-754.
Marzolini, C. et al., “Simultaneous Determination of the HIV Protease Inhibitors Indinavir, Amprenavir, Saquinavir, Ritonavir, Nelfinavir and the Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz by High-Performance Liquid Chromatography after Solid-Phase Extraction”,Journal of Chromatography B., 2000, 740(1), 43-58.
Matayoshi, E.D. et al., “Novel Flurogenic Substrates for Assaying Retroviral Proteases by Resonance Energy Transfer”,Science, 1990, 247, 954-958.
Moyle, GJ. et al., “Principles and Practice of HIV-Protease Inhibitor Pharmacoenhancement”,HIV Medicine, 2001, 2, 105-113.
Taliani, M. et al., “A Continuous Assay of Hepatitis C Virus Protease Based on Resonance Energy Transfer Depsipeptide Substrates”,Analytical Biochemistry, 1996, 240, 60-67.
Zhang, R. et al., “A Continuous Spectrophotometric Assay for the Hepatitis C Virus Serine Protease”,Analytical Biochemistry, 1999, 270, 268-275.
Toth, M.V. et al., “A Simple, Continuous Flurometric Assay for HIV Protease”,Int. J. Peptide Protein Res., 1990, 36(6), 544-550.
Tyagi, S.C. et al., “Continuous Assay of the Hyrdolytic Activity of Human Immunodeficiency Virus-1 Protease”,Analytical Biochemistry, 1992, 200(1), 143-148.
Villani, P. et al., “Antireovirals: Simultaneous Determination of Five Protease Inhibitors and Three Nonnucleoside Transcriptase Inhibitors in Human Plasma by a Rapid High-performance Liquid Chromatography-Mass Spectrometry Assay”,Therapeutic Drug Monitoring., 2001, 23(4),380-388.
Wang, G.T. et al., “Design and Synthesis of New Flurogenic HIV Protease Substrates Based on Resonance Energy Transfer”,Tetrahedron Letters, 1990, 31(45), 6493-6496.
Warner, A., “Setting Standards of Practice in Therapeutic Drug Monitoring and Clinical Toxicology: A North American View”,Therapeutic Drug Monitoring, 2001, 23(2),93-97.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Protease assay for therapeutic drug monitoring does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protease assay for therapeutic drug monitoring, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease assay for therapeutic drug monitoring will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3947406

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.